Kimio Watanabe

Dr. Kimio Watanabe


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in NeuroToxicology
Verified
Journal Article
Closed access
KWKimio Watanabe
Kimio Watanabe
TWTsuyoshi Watanabe
Tsuyoshi Watanabe
MNMasaaki Nakayama
Masaaki Nakayama

Verified
Journal Article
Open access
PDF file
KWKimio Watanabe
Kimio Watanabe
ESEmiko Sato
Emiko Sato
Eikan MishimaEikan Mishima
Eikan Mishima
MMMariko Miyazaki
Mariko Miyazaki
TTTetsuhiro Tanaka
Tetsuhiro Tanaka
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease, including end-stage kidney disease, and increases the risk of cardiovascular mortality. Although the treatment options for DKD, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists, have advanced, their efficacy is still limited. Thus, a deeper understanding of the molecular mechanisms of DKD onset and progression is necessary for the development of new and innovative treatments for DKD. The complex pathogenesis of DKD includes various different pathways, and the mechanisms of DKD can be broadly classified into inflammatory, fibrotic, metabolic, and hemodynamic factors. Here, we summarize the recent findings in basic research, focusing on each factor and recent advances in the treatment of DKD. Collective evidence from basic and clinical research studies is helpful for understanding the definitive mechanisms of DKD and their regulatory systems. Further comprehensive exploration is warranted to advance our knowledge of the pathogenesis of DKD and establish novel treatments and preventive strategies.

7 January 2014 in Toxins
Verified
Journal Article
Open access
PDF file
KWKimio Watanabe
Kimio Watanabe
KOKana Okada
Kana Okada
RFRyoji Fukabori
Ryoji Fukabori
YHYoshimitsu Hayashi
Yoshimitsu Hayashi
KAKoichi Asahi
Koichi Asahi
MNMasaaki Nakayama
Masaaki Nakayama
Methylglyoxal (MG), one of the uremic toxins, is a highly reactive alpha-dicarbonyl compound. Recent clinical studies have demonstrated the close associations of cognitive impairment (CI) with plasma MG levels and presence of kidney dysfunction. Therefore, the present study aims to examine whether MG is a direct causative substance for CI development. Eight-week-old male Sprague-Dawley (SD) rats were divided into two groups: control (n = 9) and MG group (n = 10; 0.5% MG in drinking water), and fed a normal diet for 12 months. Cognitive function was evaluated by two behavioral tests (object exploration test and radial-arm maze test) in early (4–6 months of age) and late phase (7–12 months of age). Serum MG was significantly elevated in the MG group (495.8 ± 38.1 vs. 244.8 ± 28.2 nM; p < 0.001) at the end of study. The groups did not differ in cognitive function during the course of study. No time-course differences were found in oxidative stress markers between the two groups, while, antioxidants such as glutathione peroxidase and superoxide dismutase activities were significantly increased in the MG group compared to the control. Long-term MG administration to rats with normal kidney function did not cause CI. A counter-balanced activation of the systemic anti-oxidant system may offset the toxicity of MG in this model. Pathogenetic significance of MG for CI requires further investigation.

31 October 2017 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MNMasaaki Nakayama
Masaaki Nakayama
WZWan-Jun Zhu
Wan-Jun Zhu
KWKimio Watanabe
Kimio Watanabe
AGAyano Gibo
Ayano Gibo
ASAli M. Sherif
Ali M. Sherif
Sadayoshi ItoSadayoshi Ito
Sadayoshi Ito
Peritoneal dialysis (PD) is used as renal replacement therapy in patients with end-stage kidney disease. However, peritoneal membrane failure remains problematic and constitutes a critical cause of PD discontinuation. Recent studies have revealed the unique biological action of molecular hydrogen (H2) as an anti-oxidant, which ameliorates tissue injury. In the present study, we aimed to examine the effects of H2 on the peritoneal membrane of experimental PD rats. Eight-week-old male Sprague-Dawley rats were divided into the following groups (n = 8–11 each) receiving different test solutions: control group (no treatment), PD group (commercially available lactate-based neutral 2.5% glucose PD solution), and H2PD group (PD solution with dissolved H2 at 400 ppb). Furthermore, the influence of iron (FeCl3: 5 μM: inducer of oxidative cellular injury) in the respective PD solutions was also examined (Fe-PD and Fe-H2PD groups). The H2PD solution was manufactured by bathing a PD bag in H2-oversaturated water created by electrolysis of the water. Twenty mL of the test solutions were intraperitoneally injected once a day for 10 days. Parietal peritoneum samples and cells collected from the peritoneal surface following treatment with trypsin were subjected to analysis. In the PD group as compared to controls, a mild but significant sub-mesothelial thickening was observed, with increase in the number of cells in the peritoneal surface tissue that were positive for apoptosis, proliferation and vimentin, as seen by immunostaining. There were significantly fewer of such changes in the H2PD group, in which there was a dominant presence of M2 (CD163+) macrophages in the peritoneum. The Fe-PD group showed a significant loss of mesothelial cells with sub-mesothelial thickening, these changes being ameliorated in the Fe-H2PD group. H2-dissolved PD solutions could preserve mesothelial cells and peritoneal membrane integrity in PD rats. Clinical application of H2 in PD could be a novel strategy for protection of peritoneal tissue during PD treatment.

6 December 2012 in Clinical and Experimental Nephrology
Verified
Journal Article
Closed access
PDF file
KWKimio Watanabe
Kimio Watanabe
YTYoshihiro Tani
Yoshihiro Tani
KTKenichi Tanaka
Kenichi Tanaka
YHYoshimitsu Hayashi
Yoshimitsu Hayashi
KAKoichi Asahi
Koichi Asahi
TWTsuyoshi Watanabe
Tsuyoshi Watanabe

1 January 2017 in Internal Medicine
Verified
Journal Article
Open access
PDF file
MYMidori Sasaki Yatabe
Midori Sasaki Yatabe
KWKimio Watanabe
Kimio Watanabe
YHYoshimitsu Hayashi
Yoshimitsu Hayashi
JYJunichi Yatabe
Junichi Yatabe
SMSatoshi Morimoto
Satoshi Morimoto
TWTsuyoshi Watanabe
Tsuyoshi Watanabe
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies